[6] T Okazaki et al., (2007), PD-1 and PD-1 ligands: from discovery to clinical application, International Immunology, DOI:https://doi.org/10.1093/intimm/dxm057 [7] Y Ishida et al., (1992), Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon pr...
[6] T Okazaki et al., (2007), PD-1 and PD-1 ligands: from discovery to clinical application, International Immunology, DOI: https://doi.org/10.1093/intimm/dxm057 [7] Y Ishida et al., (1992), Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon ...
[3] Keir ME, Butte MJ, Freeman GJ,Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol.2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. PMID: 18173375. [4] Pardoll DM. The blockade ofimmune checkpoints in cancer i...
PD-1 and its ligands in tolerance and immunity [J]. Annu. Rev. Immunol., 2008,26: 677-704.[7] Sheppard K A, Fitz L J, Lee J M, et al. PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ [J]. FEBS letters, ...
【1】 Taku Okazaki and Tasuku Honjo,PD-1 and PD-1 ligands: from discovery to clinical application,The Japanese Society for Immunology. 2007,International Immunology, Vol. 19, No. 7, pp. 813–824 【2】王水英,孙宁,金惠,程晓东,PD-1/PD-LS 信号通路在肿瘤免疫逃逸及治疗中的作用;医学综述 2013....
[9].Sasikumar pottayil et al. A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse eventsJournal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):O24 ...
[9].Sasikumar pottayil et al. A novelpeptide therapeutic targeting PD1 immune checkpoint with equipotent antagonismof both ligands and a potential for better management of immune-related adverseeventsJournal for ImmunoTherapy of Cancer 2013, 1(S...
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19): 5064-5074.Taube JM, Klein A, Brahmer JR et al (2014) Association... JM Taube,A Klein,JR Brahmer,... - 《Clinical Cancer ...
[3] Keir ME, Butte MJ, Freeman GJ,Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol.2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. PMID: 18173375. [4] Pardoll DM. The blockade ofimmune checkpoints in cancer immunotherapy. Nat Rev Cancer. ...
pd-1主要表达于激活的效应t细胞、调节性t细胞、b细胞、单核细胞、和天然杀伤t细胞表面,不表达于静息t细胞,但可在t细胞活化的数小时内检测到(keirme,buttemj,etal.pd-1anditsligandsintoleranceandimmunity.annualreviewofimmunology,2008,26:677-704.)。pd-1有两个配体,即pd-l1与pd-l2。其中,pd-l1广泛表达于...